ArticleFrontiers in oncology2025
Deep-learning radiomics and hand-crafted radiomics utilizing contrast-enhanced MRI to predict early peritumoral recurrence after DEB-TACE with hepatocellular carcinoma: a two-center study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate early peritumoral recurrence (EPR) after drug-eluting bead transarterial chemoembolization (DEB-TACE) in a multicenter cohort of patients with hepatocellular carcinoma (HCC) using deep learning radiomics (DLR) based on preoperative multiphase magnetic resonance imaging (MRI). Patients and methods: A total of 157 patients with HCC from two institutions who received DEB-TACE were retrospectively enrolled and divided into a training cohort (n=114) and an external validation cohort (n=43). A total of 960 radiomics features were extracted from five different phases: arterial phase (AP), delayed phase (DP), portal venous phase (PVP), peritumoral 3 mm portal venous phase (PVP_Pri3mm), and tumoral plus peritumoral portal venous phase (PVP_Plus3mm). A total of 512 deep learning features were extracted from PVP using ResNet34 (PVP_DLR). The features selected through the minimum Redundancy and Maximum Relevance (mRMR) and Least Absolute Shrinkage and Selection Operator (LASSO) methods were utilized for model construction. The performance of the model was evaluated using area under the curve (AUC), calibration curves, net reclassification (NRI), and decision curve analysis (DCA). Results: PVP_Pri3mm and PVP_Plus3mm showed comparable performance to the PVP model (P>0.05). The final deep learning radiomics and radiomics nomogram (DLRRN) included three predictors: PVP-signature, PVP_ DLR signature, and AFP, which showed effectively discrimination of between EPR to DEB-TACE, with AUCs of 0.802 (95% CI, 0.718-0.887) in the training cohort and 0.770 (95% CI, 0.623-0.916) in the external validation cohort, demonstrating good calibration (P>0.05). Additionally, the DLRRN model performed significantly better than the clinical model (P<0.05). DCA confirmed that DLRRN was clinically useful. Conclusion: DLRRN has good efficacy in predicting EPR after DEB-TACE, which can provide value for preoperative treatment selection and postoperative prognostic assessment of patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.